Information for Health Professionals, seasonal
Etiam aliguam lorem massa, et semper justo suscipit nec. Postmarketing cases of edema and fluid retention occurring within weeks of starting opsumit, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported. Nulla in luctus quam. Chat Live Online, chat live for medical/ scientific information on select Pfizer prescription medicines. Clinical Trials, access to information on clinical trials for a range of diseases and conditions. South San Francisco, CA: Actelion Pharmaceuticals US, Inc. All females, regardless of reproductive potential, must enroll in the opsumit rems Program prior to initiating opsumit. Hemoglobin Decrease, decreases in hemoglobin concentration and hematocrit have occurred following administration of other ERAs and in clinical studies with opsumit. Measure hemoglobin prior to initiation of treatment and repeat during treatment as clinically indicated. Advise patients to report symptoms suggesting hepatic injury (nausea, vomiting, right upper quadrant pain, fatigue, anorexia, jaundice, dark urine, fever, or itching).
Healthcare Professionals, children's Hospital
There is no fee to register or use MyBlue. Strong inhibitors of CYP3A4 like ketoconazole approximately double macitentan exposure. Available 9am-5pm ET Mon-Fri, recent Announcements. Healthcare Professional Registration, conduct a Fee Schedule Search, check Patient Eligibility Benefits. A decrease in hemoglobin to below.0 g/dL was reported.7 of the opsumit group.4 for placebo. Text area to explain about the registration process and restricted documents. If confirmed, discontinue opsumit. Many HIV drugs like ritonavir are strong inhibitors of CYP3A4. Obtain liver enzyme tests prior to initiation of opsumit and repeat during treatment as clinically indicated. Decreases in hemoglobin seldom require transfusion. Drug interactions, strong inducers of CYP3A4 such as rifampin significantly reduce macitentan exposure. In the seraphin study, opsumit caused a mean decrease in hemoglobin (from baseline to 18 months) of about.0 g/dL vs no change in the placebo group. Donec sit amet ligula in nque dapibus sagittis.
Information for healthcare professionals
Initiation of opsumit is not recommended in patients with severe anemia. Prevent pregnancy during treatment and for one month after stopping treatment by using acceptable methods of contraception. Start with opsumit to reduce the risk of disease progression in PAH. In the pivotal PAH study seraphin, edema was reported.9 of the opsumit group.5 for placebo. Disease progression included: death, initiation of intravenous (IV) or subcutaneous prostanoids, or clinical worsening of PAH (decreased 6-minute walk distance, worsened PAH symptoms and need for additional PAH treatment). Monitor for signs of fluid retention after opsumit initiation. Counsel men about potential effects on fertility. Pulmonary Edema with Pulmonary Veno-occlusive Disease (pvod). Back TO TOP, important safety information, boxed warning: embryo-fetal toxicity. Use other PAH treatment options when strong CYP3A4 inhibitors are needed as part of HIV treatment. Consider re-initiation of opsumit when hepatic enzyme levels normalize in patients who have not experienced clinical symptoms of hepatotoxicity. For females of reproductive potential, exclude pregnancy prior to initiation of therapy, ensure use of acceptable contraceptive methods, and obtain monthly pregnancy tests. For all female patients, opsumit is available only through a restricted program called the opsumit Risk Evaluation and Mitigation Strategy (rems).